JP3973424B2 - テルビナフィンに対する特異的モノクローナル抗体 - Google Patents

テルビナフィンに対する特異的モノクローナル抗体 Download PDF

Info

Publication number
JP3973424B2
JP3973424B2 JP2001558737A JP2001558737A JP3973424B2 JP 3973424 B2 JP3973424 B2 JP 3973424B2 JP 2001558737 A JP2001558737 A JP 2001558737A JP 2001558737 A JP2001558737 A JP 2001558737A JP 3973424 B2 JP3973424 B2 JP 3973424B2
Authority
JP
Japan
Prior art keywords
terbinafine
antibody
antibodies
conjugate
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001558737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522537A (ja
Inventor
ビルギット・ドロベク
ペーター・ヌスバウマー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2003522537A publication Critical patent/JP2003522537A/ja
Application granted granted Critical
Publication of JP3973424B2 publication Critical patent/JP3973424B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2001558737A 2000-02-14 2001-02-12 テルビナフィンに対する特異的モノクローナル抗体 Expired - Fee Related JP3973424B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0003360.5A GB0003360D0 (en) 2000-02-14 2000-02-14 Monoclonal antibodies
GB0003360.5 2000-02-14
PCT/EP2001/001535 WO2001059458A1 (en) 2000-02-14 2001-02-12 Specific monoclonal antibody against terbinafine

Publications (2)

Publication Number Publication Date
JP2003522537A JP2003522537A (ja) 2003-07-29
JP3973424B2 true JP3973424B2 (ja) 2007-09-12

Family

ID=9885556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001558737A Expired - Fee Related JP3973424B2 (ja) 2000-02-14 2001-02-12 テルビナフィンに対する特異的モノクローナル抗体

Country Status (8)

Country Link
US (1) US7122184B2 (de)
EP (1) EP1261874B1 (de)
JP (1) JP3973424B2 (de)
AT (1) ATE469352T1 (de)
AU (1) AU3546701A (de)
DE (1) DE60142225D1 (de)
GB (1) GB0003360D0 (de)
WO (1) WO2001059458A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200821276A (en) * 2006-08-18 2008-05-16 Leo Pharma As Substituted acetylenic compounds useful for the treatment of diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2526423B1 (fr) 1982-05-07 1987-07-10 Sandoz Sa Nouvelles amines insaturees, leur preparation et leur utilisation comme medicaments
US5169773A (en) * 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
IT1261776B (it) 1993-03-12 1996-06-03 Mendes Srl Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
IL109159A (en) 1993-03-29 2003-11-23 Isk Biotech Corp Immunoassays for tetrachloroiso-phthalonitrile and its metabolites and antibodies for use therein
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
IT1284076B1 (it) * 1996-06-27 1998-05-08 Dox Al Italia Spa Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro

Also Published As

Publication number Publication date
GB0003360D0 (en) 2000-04-05
WO2001059458A1 (en) 2001-08-16
JP2003522537A (ja) 2003-07-29
ATE469352T1 (de) 2010-06-15
DE60142225D1 (en) 2010-07-08
AU3546701A (en) 2001-08-20
US20030087323A1 (en) 2003-05-08
EP1261874B1 (de) 2010-05-26
US7122184B2 (en) 2006-10-17
EP1261874A1 (de) 2002-12-04

Similar Documents

Publication Publication Date Title
KR20150014996A (ko) 항-토파시티닙 항체 및 약물을 모니터링하기 위한 그의 용도
JPWO2009075376A1 (ja) 抗オフロキサシンモノクローナル抗体、これを用いたオフロキサシンの免疫学的測定方法
US20220119546A1 (en) Plectin-1 binding antibodies and uses thereof
US6946547B2 (en) Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
JP5798679B2 (ja) ヒト肝−カルボキシルエステラーゼ１を特異的に認識するモノクローナル抗体、前記抗体を生産するハイブリドーマ細胞株及びその用途
JP3973424B2 (ja) テルビナフィンに対する特異的モノクローナル抗体
US8673652B2 (en) Immunoassay with extended detection window
US6814951B1 (en) Acetaldehyde and malondialdehyde protein adducts as markers for alcohol liver disease
JP2732825B2 (ja) 新規なベンゾジアゼピン−タンパク質結合体
WO1997016727A1 (en) Assay background reduction using glycoproteins with oxidized carbohydrates
JP4663831B2 (ja) モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
YONG-CHENG et al. Production and characterization of anti-estrone monoclonal antibody
US7348412B1 (en) Ouabain-specific monoclonal antibodies
JP2011017697A (ja) 抗オフロキサシンモノクローナル抗体、これを用いたオフロキサシンの免疫学的測定方法
EP1707576A1 (de) Methyllysin erkennende antikörper, verfahren zu deren herstellung und deren anwendung
JP4037933B2 (ja) 抗ヒトカルシトニンモノクローナル抗体
US6120777A (en) High fluorescence specific immune enhancing factor and methods of use for same
JPH07209295A (ja) 抗体及び酵素標識抗原並びにこれらを用いる酵素免疫測定法及び測定用キット
JP4664340B2 (ja) モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
US6291198B1 (en) Antibody that recognizes pyrazine derivative and method for measuring 1,2-dicarbonyl derivative using said antibody
JP4393210B2 (ja) 抗体およびその用途
JP3479453B2 (ja) 尿中テガフールの測定法
Kitjaroentham et al. Monoclonal antibodies to quinine
JP2005143504A (ja) 抗体およびその用途
JPH11181000A (ja) ピラジン誘導体認識抗体及びそれを用いた１，２−ジカルボニル誘導体の測定方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070612

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100622

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110622

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees